Colchicine, A Potential First-Line Treatment For Cutaneous Polyarteritis Nodosa: Study
- byDoctor News Daily Team
- 03 August, 2025
- 0 Comments
- 0 Mins

Paris: Colchicine is a reasonable first-line treatment for cutaneous polyarteritis nodosa (cPAN) without peripheral sensory neuropathy and has a favorable risk-to-benefit ratio, a recent study has found.
The study, published in the Journal of the American Academy of Dermatology, suggests the use of glucocorticoids (GCs) + azathioprine for patients with sensory neuropathy.
Cutaneous polyarteritis nodosa (cPAN) is a form of medium-sized vessel vasculitis. Despite it being a disabling and prolonged course, there is a lack of data on treatment efficacy and safety. To fill this knowledge gap, Alexis Régent, Université de Paris, Paris, and colleagues aimed to describe treatment efficacy and safety in patients with cPAN.
For this purpose, the researchers conducted a multicentre retrospective observational study. They recorded clinical and biological data together with treatments received. The primary outcome was the rate of complete response (CR) at month 3. Secondary outcomes included drug survival, and safety was assessed.
Also Read: Colchicine beneficial in COVID-19 RTCPR confirmed cases, Lancet study
A total of 68 patients who received a median of 2 therapeutic lines (interquartile range 1-3) were included.
The research yielded the following findings:
Overall, 31% patients achieved CR with colchicine, 23% with dapsone, 44% with glucocorticoids (GCs) alone, 11% with NSAIDs, 84% with GCs+azathioprine (AZA) and 47% with GCs+methotrexate.
GCs+AZA had the best drug survival (median duration 29.5 months).
Response at month 3 was decreased with peripheral neurological involvement (odds ratio 0.19).
Overall, the rate of treatment-related adverse events was 18%, which led to treatment discontinuation in 7% of patients.
"Colchicine seems to confer good benefit–risk balance in cPAN without peripheral sensory neuropathy," wrote the authors. "GCs+AZA seems the best treatment for disease relapse."
Also Read: Azathioprine as good as Mycophenolate mofetil for immunosuppression after kidney transplant: Study
Reference:
The study titled, "Efficacy and safety of treatments in cutaneous polyarteritis nodosa: a French observational retrospective study," is published in the Journal of the American Academy of Dermatology.
DOI: https://www.jaad.org/article/S0190-9622(21)02021-1/fulltext
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
Recent News
Chennai: Fortis Healthcare Opens 250-Bedded 2nd Mu...
- 06 July, 2025
New Lab-On-A-Chip, Cheaper, Faster, On The Spot Di...
- 06 July, 2025
Steroids And Plasma Exchange Do Not Alter Prognosi...
- 14 February, 2020
Daily Newsletter
Get all the top stories from Blogs to keep track.
0 Comments
Post a comment
No comments yet. Be the first to comment!